This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Starling Oncology Institute (STLN), Axsome Therapeutics (AXSM) and Contineum Therapeutics, Inc. Class A (CTNM)

Tipranks - Tipranks - Thu Oct 15, 6:55AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Starling Oncology Institute (STLN), Axsome Therapeutics (AXSM) and Contineum Therapeutics, Inc. Class A (CTNM) with bullish sentiments.

Starling Oncology Institute (STLN)

In a report released today, Matthew Shea from Needham reiterated a Buy rating on Starling Oncology Institute, with a price target of $9.00. The company’s shares closed last Tuesday at $6.70.

According to TipRanks.com, Shea is a 4-star analyst with an average return of 15.3% and a 53.6% success rate. Shea covers the Healthcare sector, focusing on stocks such as Evolent Health, Astrana Health, and Agilon Health. ;'>

Currently, the analyst consensus on Starling Oncology Institute is a Strong Buy with an average price target of $9.67.

See Insiders’ Hot Stocks on TipRanks >>

Axsome Therapeutics (AXSM)

RBC Capital analyst Leonid Timashev maintained a Buy rating on Axsome Therapeutics today and set a price target of $295.00. The company’s shares closed last Tuesday at $156.32.

According to TipRanks.com, Timashev is a 5-star analyst with an average return of 17.1% and a 51.7% success rate. Timashev covers the Healthcare sector, focusing on stocks such as NewAmsterdam Pharma Company, Praxis Precision Medicines, and Perspective Therapeutics. ;'>

Currently, the analyst consensus on Axsome Therapeutics is a Strong Buy with an average price target of $287.87, implying a 73.4% upside from current levels. In a report issued on September 29, Deutsche Bank also maintained a Buy rating on the stock with a $267.00 price target.

Contineum Therapeutics, Inc. Class A (CTNM)

In a report released today, Debanjana Chatterjee from JonesTrading maintained a Buy rating on Contineum Therapeutics, Inc. Class A, with a price target of $30.00. The company’s shares closed last Tuesday at $8.42, close to its 52-week low of $5.92.

According to TipRanks.com, Chatterjee is a 5-star analyst with an average return of 33.9% and a 58.1% success rate. Chatterjee covers the Healthcare sector, focusing on stocks such as Sagimet Biosciences, Inc. Class A, EyePoint Pharmaceuticals, and Armata Pharmaceuticals. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Contineum Therapeutics, Inc. Class A with a $22.14 average price target, which is a 158.6% upside from current levels. In a report issued on September 29, LifeSci Capital also maintained a Buy rating on the stock with a $23.00 price target.

Read More on STLN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
Market data provided by Barchart. Exchange delay details and data provider terms here. Information may be delayed, is provided 'as is' and is solely for informational purposes, and not for trading, investment or advice.